News

  Parma, 22 September 2026 – Maria Paola Chiesi, Chair of the Board of Chiesi Group, has joined the Chairs of several leading healthcare companies in signing an open letter urging policymakers to consider investment in health and innovation as a strategic priority for Europe's future competitiveness, resilience, and health sovereignty.   The letter highlights the strategic importance of the pharmaceutical sector for Europe's economy, healthcare systems, and scientific leadership, while warning that the region is increasingly losing ground to other global markets in research, development, and investment.   The signatories call on European and national leaders to take action to foster innovation, accelerate clinical research, improve patient access to new medicines, and create conditions that attract long-term investment in life sciences.   Read the full letter here

Chiesi Farmaceutici has announced a strategic partnership with Abdi İbrahim to implement a new operating model for Chiesi’s business in Türkiye. Effective 1 October 2026, the partnership will combine Chiesi's global scientific expertise, innovative portfolio and high-quality standards with Abdi İbrahim's strong local capabilities, market reach and nationwide commercial infrastructure. Under the new operating model, products from Chiesi Türkiye's portfolio in Respiratory Health, Neonatology and Rare Diseases will continue to be available to patients and healthcare professionals across Türkiye, reflecting Chiesi’s commitment to improve people’s quality of life and ensure that no patient is left behind.

Following Chiesi's evaluation of the seralutinib development program and the PROSERA Phase 3 study results, Chiesi and Gossamer Bio have agreed to terminate their Collaboration and License Agreement related to the development and commercialization of seralutinib for the treatment of patients with pulmonary hypertension (PAH) and additional indications.    As part of the agreement announced today, Chiesi is returning the worldwide development and commercial rights related to seralutinib to Gossamer Bio, while remaining entitled to a capped royalty on worldwide net sales of seralutinib, as well as payments upon the achievement of specified regulatory and commercial milestones.     The work carried out by the companies on seralutinib provided important contributions to advancing scientific understanding in this area, and Chiesi remains committed to turning top notch science into innovative solutions for patients living with chronic respiratory diseases.     While this collaboration has been concluded, Chiesi's long-standing commitment to respiratory medicine continues to be a strategic pillar for the company, and we remain focused on delivering innovation for people living with asthma, COPD, and other respiratory conditions.   For more information, read the press release on the Gossamer Bio website.     

Chiesi today announces MHRA approval in the UK of Clenil Modulite (beclometasone; 100mcg and 200mcg) formulated with a non-PFAS, low-GWP, next generation propellant (HFA-152a). These are the first pMDIs to use HFA-152a worldwide, with the UK being the first country to approve these products. Chiesi’s propellant transition is expected to cut the carbon footprint of their beclometasone products by up to 90% versus the current propellant and aims to ensure continuity of care for patients by preserving device choice while addressing the environmental impact of these pMDIs.   Read more here: https://www.chiesi.uk.com/media/press-releases/2026-07-21-clenil-mhra-approval   Discover how we’re transforming respiratory care for people and the planet: Air | Chiesi Farmaceutici S.p.A.

Chiesi Group and Oak Hill Bio Holdings have announced the completion of patient enrollment in the Phase 2b FOOTPRINTS study evaluating OHB-607 for the prevention of bronchopulmonary dysplasia (BPD), a leading cause of chronic lung disease in premature infants for which there are currently no approved therapies.    OHB-607 is an investigational therapy designed to restore physiological insulin-like growth factor-1 (IGF-1) levels following extremely premature birth.    The FOOTPRINTS study enrolled 352 extremely premature infants born between 23 and 28 weeks of gestation across neonatal centers in North America, Europe, the United Kingdom, Japan, and Australia. The primary endpoint of the study is the reduction in the incidence of severe BPD or mortality by 36 weeks postmenstrual age (PMA) compared with standard neonatal care alone. The study will also assess longer-term respiratory, safety, and neurodevelopmental outcomes through 24 months corrected age.    Topline results from the FOOTPRINTS study are expected in early 2027.    Read more on the website of Oak Hill Bio Holdings.  

Parma, Italy – 18 May 2026   Chiesi announces that the U.S. Food and Drug Administration (FDA) has approved its single-inhaler triple therapy (beclomethasone dipropionate/formoterol fumarate/glycopyrrolate; BDP/FF/G) for the maintenance treatment of asthma in adults.    The approval was supported by two Phase 3 clinical trials (TRIMARAN and TRIGGER) that evaluated safety and efficacy in more than 2,500 adults with uncontrolled asthma. Across the studies, BDP/FF/G demonstrated improvements in lung function compared with BDP/FF.    The safety profile was comparable with BDP/FF, with commonly reported adverse events including asthma exacerbation, nasopharyngitis and headache (among others).    Outside the United States, Chiesi’s single-inhaler triple therapy is commercialized in nearly 50 countries, including the European Union, the United Kingdom and China.